Pubblicazioni

Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA

2022 - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Ruiz, Irene Canales; Martelli, Maurizio; Sehn, Laurie H; Vitolo, Umberto; Nielsen, Tina G; Sellam, Gila; Bottos, Alessia; Klingbiel, Dirk; Kostakoglu, Lale

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study

2021 - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Lawless, S; Sbianchi, G; Morris, C; Iacobelli, S; Bosman, P; Blaise, D; Remenyi, P; Byrne, Jl; Mayer, J; Apperley, J; Lund, J; Kobbe, G; Schaap, N; Isaksson, C; Lenhoff, S; Basak, G; Touzeau, C; Wilson, Kmo; Muniz, Sg; Scheid, C; Browne, P; Anagnostopoulos, A; Rambaldi, A; Jantunen, E; Kroger, N; Schonland, S; Yakoub-Agha, I; Garderet, L